V

Viatris

Global pharma selling generics and biosimilars

Financial Master Data Analyst

Full-TimePosted on 10/23/2026Deadline 11/23/26
No salary listed
Mid
Bachelor's
Remote in Costa Rica
RemoteRemote role in Costa Rica.
AccountingFinancial Accounting

About the job

Requirements
  • Awareness of systems and requirements relating to master data processing, including forms, approvals, and policy.
  • Knowledge of chart of accounts and maintenance, including account types, normal balances, and where and how accounts are used.
  • Knowledge of Hyperion or other financial reporting tools and their master data maintenance activities.
  • Good working knowledge of Microsoft Office Suite, particularly Excel and Outlook, and related tools.
  • Awareness of internal controls and mitigations, including SOX compliance.
  • Awareness of U.S. Generally Accepted Accounting Principles.
  • Ability to understand multi-dimensional approval matrices and translate them into system approval rules.
  • Ability to interpret and analyze customer requests and make master data recommendations for accurate, policy-aligned execution.
  • Ability to see both the macro and micro view of requests and determine the best course for implementation.
  • Ability to work independently and as a team member.
  • Ability to communicate and interact clearly, effectively, and professionally in English verbally and in writing with the core FMD virtual team and diverse global users.
  • Ability to collect data and perform data and risk analysis to reach a logical conclusion or solution to a request.
  • Ability to quickly identify and resolve finance master data issues.
  • Ability to rank and prioritize work for timely delivery.
  • Ability to meet individual and department deadlines with minimal supervision.
  • Ability to plan, organize, and execute master data maintenance in accordance with established procedures.
  • Ability to create and manage related process documentation.
  • Strong organizational skills for managing requests from across the globe.
  • Minimum of a Bachelor's degree or equivalent experience; the posting specifies 2–4 years of experience.
  • Experience in the finance-related industry for 2–4 years.
  • English proficiency at B2 minimum.
  • Ability to read and interpret complex business and/or technical documents.
  • Ability to write business correspondence in English.
  • Ability to work with groups of people, including other departments, and communicate known concepts.
  • Ability to present to a group.
  • Ability to apply logic and quantitative reasoning.
  • Ability to draw inferences and follow prescribed, detailed procedures in all scenarios.
Responsibilities
  • Create and maintain financial master data to support business processes, including approval flow mapping; Chart of Accounts for GL Accounts and Cost Elements; Cost Centers and Cost Center standard hierarchy; Profit Centers and Profit Center standard hierarchy; bank keys; foreign exchange rates; and financial statement versions, in accordance with company policy. Maintain approvers for the company's Global E-Procurement tool, Legal Contracts Management tool, and invoice approval routing and reconciliation tool.
  • Support the collection of master data, related financial reporting mapping, and approval mapping for a variety of system requirements.
  • Ensure financial master data is evaluated and created so that processes function efficiently, effectively, and in accordance with company policy.
  • Manage user requests for new master data and changes to existing master data.
  • Track assigned financial master data requests and prioritize them according to established guidelines and Service Level Agreements.
  • Maintain and update training material, process documentation, and forms related to financial master data collection and maintenance.
  • Maintain effective communications with key internal and external partners and the core FMD virtual team.
  • Provide master data guidance and training when appropriate.
  • Solve issues and scenarios and perform data and risk analysis of varying complexity, following established policies and procedures to reach a logical conclusion or solution.
  • Support and participate in master data maintenance activities for system implementations, upgrades, enhancements, integrations, legal entity consolidations, and other business-driven projects.
  • Support and ensure adherence to defined Service Level Agreements.
  • Collaborate with the core FMD virtual team on work beyond normal business-as-usual tasks, including integrations, enhancements, and business directives.
  • Identify process improvement opportunities.
  • Support ERP project implementations and coordinate efforts with stakeholders and the business to support these projects from the FMD perspective.
  • Support Approval & Authorizations (CFA) activities and related processes.
  • Perform other duties assigned according to FMD operational process requirements.
Desired Qualifications
  • Experience in Finance, Accounting, or Financial Planning & Analysis; a combination of experience and/or education will be considered.
  • SAP experience.
  • Experience in data analytics and auditing.
  • Portuguese language skills.

About the company

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue rose 5% to $3.8 billion, and guidance increased.
  • Debt fell after $900 million repayment, reducing gross leverage to 2.9x.
  • Tyrvaya divestiture, Gwyn Lo, and meloxicam NDA support a higher-value portfolio shift.

What critics are saying

  • Nashik fire and FDA Form 483 disruptions cut second-half 2026 revenue by $100-$150 million.
  • Greater China procurement changes pressure hospital volumes, squeezing one of Viatris's fastest growth engines.
  • Generic pricing MDL and ongoing patent fights in Japan keep legal overhangs persistent.

What makes Viatris unique

  • Viatris pairs 165-country reach with complex generics, branded drugs, and biosimilars.
  • Japan approved WAKIX on September 16, 2026, expanding first-in-class sleep medicine reach.
  • FDA approved Gwyn Lo on July 29, 2026, adding a differentiated women’s health product.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Wellness Program
  • Paid Holidays

Growth & Insights and Company News

6 month growth

18%

1 year growth

18%

2 year growth

18%
PR Newswire
Oct 16th, 2026
Viatris wins FDA approval for Ryzumvi to treat presbyopia in adults

Viatris has won US Food and Drug Administration (FDA) approval for RYZUMVI (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults, the company announced on October 16, 2026. RYZUMVI was already approved in the US for pharmacologically-induced mydriasis, and is the only commercially available FDA-approved product for that use. The new approval adds presbyopia to its indications. Viatris is exploring a US partner to commercialise the product for presbyopia. Under a global licensing agreement with Opus Genetics, Viatris holds exclusive US commercial rights. Presbyopia is the gradual loss of near focusing ability with age, typically noticeable in the early to mid-40s.

South Jordan Journal
Oct 8th, 2026
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

The South Jordan Journal is the local newspaper covering news and events in the City of South Jordan, Utah. The South Jordan Journal provides one of the best advertising channels to the residents of the City of South Jordan.

Yahoo Finance
Sep 24th, 2026
Viatris stock surges 78% in a year, outpacing S&P 500 with strong portfolio growth

Viatris Inc., a global pharmaceutical company based in Canonsburg, Pennsylvania, has significantly outperformed the S&P 500. The stock surged 8.7% over the past three months, compared to the index's 4.7% gain. Year to date, shares climbed 37.5%, whilst the S&P 500 rose 12.6%. With a market cap of $10.4 billion, Viatris operates in 165+ countries and covers more than 10 major therapeutic areas. The company sells more than 80 billion doses annually across 1,400 approved molecules. On 16 September, shares jumped 2.2% after Japan approved WAKIX for treating excessive daytime sleepiness. The company's strong performance stems from improved business momentum, solid cash generation, and progress in its higher-value product portfolio.

PR Newswire
Sep 16th, 2026
Japan approves Viatris' Wakix for narcolepsy and sleep apnoea-related daytime sleepiness

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy. WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan for these conditions. The treatment addresses excessive daytime sleepiness, a symptom affecting both conditions that can significantly impact daily functioning and quality of life. WAKIX is not classified as a controlled substance and has been designated an orphan drug in Japan for narcolepsy. The approval was supported by positive data from domestic Phase 3 clinical trials in Japan and international studies. WAKIX, discovered by Bioprojet and licensed to Viatris for Japan, has previously received approvals in more than 38 countries for narcolepsy.

Yahoo Finance
Aug 13th, 2026
Viatris delivers $3.8B revenue with 3.5% growth, raises outlook after strong Q2 2026

Viatris reported strong Q2 2026 results, with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year. The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69. CEO Scott Smith highlighted strong commercial performance across the company's global portfolio, particularly in Greater China where investments in established brands drove meaningful growth. North America also saw solid growth from complex generics and transdermal products. The company announced US regulatory approval for Gwyn Lo last week, with a launch planned for later this year. Fast-acting meloxicam continues through FDA review, with launch preparations underway. Based on the strong quarterly performance, Viatris raised its outlook for the remainder of 2026. The results exceeded company expectations and demonstrated continued improvement in operating leverage.